Sensus Healthcare (NASDAQ:SRTS) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen lowered shares of Sensus Healthcare (NASDAQ:SRTS) from a sell rating to a strong sell rating in a report issued on Saturday morning.

A number of other equities analysts have also commented on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Tuesday, April 21st. Alliance Global Partners started coverage on shares of Sensus Healthcare in a report on Friday, March 6th. They issued a “buy” rating and a $7.50 price target on the stock. Maxim Group decreased their price target on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Finally, Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a report on Friday. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.88.

Sensus Healthcare Price Performance

Shares of NASDAQ:SRTS opened at $3.08 on Friday. The company’s fifty day moving average price is $4.14 and its 200-day moving average price is $4.16. The firm has a market capitalization of $50.70 million, a price-to-earnings ratio of -6.55 and a beta of 1.19. Sensus Healthcare has a one year low of $2.82 and a one year high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The company had revenue of $3.39 million during the quarter, compared to the consensus estimate of $5.32 million. Sensus Healthcare had a negative return on equity of 15.41% and a negative net margin of 34.50%.

Hedge Funds Weigh In On Sensus Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the business. Opes Wealth Management LLC bought a new position in shares of Sensus Healthcare during the 3rd quarter valued at $50,000. XTX Topco Ltd bought a new position in shares of Sensus Healthcare during the 4th quarter valued at $77,000. Jane Street Group LLC bought a new position in shares of Sensus Healthcare during the 4th quarter valued at $79,000. Mindset Wealth Management LLC grew its holdings in shares of Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Ingalls & Snyder LLC bought a new position in shares of Sensus Healthcare during the 4th quarter valued at $219,000. Institutional investors own 25.30% of the company’s stock.

More Sensus Healthcare News

Here are the key news stories impacting Sensus Healthcare this week:

• Positive Sentiment: Sensus said it has amicably resolved its commercial dispute with SkinCure Oncology, which could reduce legal uncertainty and support a more stable operating outlook. Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
• Positive Sentiment: Management outlined a full-year profitability goal for 2026, saying new CPT codes are now taking effect and could improve reimbursement and demand trends. Sensus outlines full year profitability goal for 2026 as new CPT codes take effect
• Neutral Sentiment: Recent earnings-call coverage focused on management’s recovery narrative and operational commentary, but did not add materially new financial information beyond the quarter’s results. Sensus Healthcare Charts Recovery Path Amid Revenue Drop
• Negative Sentiment: First-quarter 2026 results showed revenue of about $3.4 million, well below the prior year’s $8.3 million, while EPS of $(0.16) missed estimates and margins remained negative, reinforcing concerns about the company’s near-term growth and profitability. Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.